<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors
Elio Adib(Dana-Farber Brigham Cancer Center), David J. Kwiatkowski(Brigham and Women's Hospital), Marios Giannakis(Broad Institute), Guru Sonpavde(AdventHealth Orlando), Toni K. Choueiri(Harvard University), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Tarek H. Mouhieddine(Icahn School of Medicine at Mount Sinai), David A. Braun(Yale Cancer Center), Kent W. Mouw(Massachusetts General Hospital), Amin H. Nassar(Brigham and Women's Hospital), Sachet A. Shukla(Broad Institute), Robert I. Haddad(Georgetown University), F. Stephen Hodi(Harvard University), Sarah Abou Alaiwi(Yale New Haven Hospital), Elie W. Akl(Brigham and Women's Hospital), Alexander Gusev(Dana-Farber Cancer Institute)
Cited by 129
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Integrative approaches for large-scale transcriptome-wide association studies
|Nature Genetics|2016|2.7k